**CONCLUSIONS**

- Imdusiran (AB-729) administered every 8 weeks in combination with pegylated interferon alfa-2a in virally suppressed HBeA-negative subjects with chronic HBV infection leads to HBSAg loss in some subjects at end of IFN treatment

  - Man Po Yuen,1,2,3 Jeong Hees,1 Ronald Nahaos,1 Grace Wong,1 Tatiana Burda,1 Kyunam Ram Bhamidimarry,1 Tsung-Hui Hsu,1,2,3 Tuan Nguyen,1,2,3 Stuart Gordon,1,2,3 Jacinta Holmes,1,2,3 Wen-Long Chiang,1,2,3 Anita Kohli,1,2,3,4 Naim Akhouri,2,3 Kevin Gray,2,3 Elena Medvedeva,2,3 Timothy Eley,2,3 Shane C. Ganch,2,3 Christina Iott,2,3 Christine L. Espiritu,2,3 Amanda Anderson,2,3 Tiffany Fortney,2,3 Gavin Cochery,2,3 Karen D. Sims,2,3 The University of Hong Kong, Hong Kong, China; King's College Hospital, London, UK; University of Washington, Seattle, WA; US National Institutes of Health, Bethesda, MD; Albert Einstein College of Medicine, Bronx, NY

  - HBeAg suppression, HBSAg seroconversion and treatment-emergent reactivation events were observed

  - More subjects in the 24-week IFN cohorts (A1/A2) reached and maintained undetectable HBSAg than in the 12-week IFN cohorts (B1/B2); extending imdusiran dosing during IFN treatment also increased rates of HBSAg loss

  - No safety signals were observed

**ACKNOWLEDGEMENTS**

Arbutus Biopharma thanks all participating subjects and their families, the Investigators and site staff, Novotech CRD and ProTrials Research, Q'T Solutions, ProProven for study conduct, and the imdusiran (AB-729) Research and Development Teams.

**REFERENCES**

- Van Den Bergh et al. 2020, 5(9):221-229.

**CONTACT INFORMATION AND DISCUSSION**

Karen Sims, MD, PhD
Chief Medical Officer
Arbutus Biopharma
Arbutus Biopharma, Inc., 701 Veterans Circle, Warminster, PA 18974
Email: ksim@arbusbio.com

Authors affiliated with Arbutus Biopharma are employees and may own company stock.

www.arbusbio.com